Related Experiment Video
Updated: Jun 24, 2026

Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
Published on: October 29, 2020
Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates
Helio S Sader1, Thomas R Fritsche, Ronald N Jones
1JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA. helio-sader@jmilabs.com
Abstract:
The in vitro activity of iclaprim, a novel diaminopyrimidine derivative, was evaluated against 5,937 recent gram-positive clinical isolates collected in the United States and Europe. Iclaprim demonstrated potent activity against Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA]), beta-hemolytic Streptococcus spp., and Enterococcus faecalis strains tested. In addition, iclaprim exhibited bactericidal activity against all S. aureus strains tested, including MRSA.
Insights
Iclaprim, a new diaminopyrimidine, shows strong in vitro activity against common gram-positive bacteria, including MRSA. It demonstrated potent and bactericidal effects against key clinical isolates like Staphylococcus aureus and Enterococcus faecalis.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Emerging antibiotic resistance poses a significant global health threat.
- Gram-positive bacterial infections remain a major cause of morbidity and mortality.
- Novel antimicrobial agents are crucial for combating resistant pathogens.
Purpose of the Study:
- To evaluate the in vitro antimicrobial activity of iclaprim, a novel diaminopyrimidine derivative.
- To assess iclaprim's efficacy against a large collection of recent gram-positive clinical isolates.
- To determine if iclaprim exhibits bactericidal activity against key resistant strains.
Main Methods:
- In vitro susceptibility testing was performed.
- A total of 5,937 clinical isolates were collected from the United States and Europe.
- Standard microbiological techniques were used to evaluate bacterial growth inhibition and bactericidal effects.
Main Results:
- Iclaprim demonstrated potent in vitro activity against Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA).
- Effective activity was observed against beta-hemolytic Streptococcus spp. and Enterococcus faecalis.
- Iclaprim exhibited bactericidal activity against all tested S. aureus strains, including MRSA.
Conclusions:
- Iclaprim is a potent antimicrobial agent against a wide range of clinically relevant gram-positive pathogens.
- Its demonstrated activity, including against MRSA, suggests potential for treating serious gram-positive bacterial infections.
- Further clinical investigation of iclaprim is warranted.
Related Concept Videos
Antimicrobial Effectiveness
Inhibitors of Gram-positive Cell Wall Synthesis
Clinical Significance of Antibiotic Resistance
Hand hygiene
Hand washing...
Inhibitors of Bacterial DNA Synthesis
Combined Effects of Drugs: Synergism
Such synergistic combinations...

